QXL138AM
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 8 by
- Accepting patients
USC Norris Comprehensive Cancer Center - Keck School of Medicine
University of Southern California
Los Angeles, CA
- Not yet accepting
Cedars-Sinai Medical Center - UCLA School of Medicine
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
- Not yet accepting
Hoag Memorial Hospital Presbyterian
Newport Beach, CA
- Not yet accepting
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
- Not yet accepting
- Not yet accepting
New York Cancer and Blood Specialists
Riverhead, NY
- Not yet accepting
- Not yet accepting
1,352 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.